NCT03849404CompletedPhase 3
A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira® in Patients With Moderate-to-Severe Chronic Plaque Psoriasis (ALVOPAD PS)
Alvotech Swiss AG30 sites in 4 countries413 target enrollmentStarted: February 20, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Alvotech Swiss AG
- Enrollment
- 413
- Locations
- 30
- Primary Endpoint
- Psoriasis Area and Severity Index (PASI)
Study Overview
Brief Summary
Safety and Efficacy study of AVT02 (Alvotech Biosimilar to Adalimumab), in patients with moderate to severe plaque psoriasis.
Detailed Description
A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira® in Patients with Moderate-to-Severe Chronic Plaque Psoriasis (ALVOPAD PS).
This study will be conducted at about 40 study centers in central and eastern European countries. A contract research organization, will oversee operational aspects of this study on behalf of Alvotech Swiss AG (Alvotech), the Sponsor of the study.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description
This is a double blind study.
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient with moderate-to-severe chronic plaque psoriasis who has involved body surface area (BSA) ≥ 10% (Palm Method), ≥ 12 on the PASI, and static Physicians Global Assessments (sPGA) ≥ 3 (moderate) at Screening and at BL.
- •Patient has had stable psoriatic disease for at least 2 months (ie, without significant changes as defined by the Investigator or designee).
- •Patient is a candidate for systemic therapy and the patient has a previous failure, inadequate response, intolerance, or contraindication to at least 1 systemic antipsoriatic therapy including, but not limited to, methotrexate, cyclosporine, psoralen plus ultraviolet light A (PUVA), and ultraviolet light B (UVB).
Exclusion Criteria
- •Patient has prior use of 2 or more biologics for treatment of PsO.
- •Patient diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, other skin conditions (eg, eczema), or other systemic autoimmune disorder inflammatory disease at the time of the Screening visit that would interfere with evaluations of the effect of the study drug on psoriasis.
- •Patient has prior use of any of the following medications within specified time periods or will require use during the study:
- •Topical medications within 2 weeks of BL (Week 1).
- •PUVA phototherapy and/or UVB phototherapy within 4 weeks prior to the BL Visit.
- •Nonbiologic psoriasis systemic therapies (eg, cyclosporine, methotrexate, and acitretin) within 4 weeks prior to the BL Visit.
- •Any prior or concomitant or biosimilar adalimumab therapy, either approved or investigational.
- •Any systemic steroid in the 4 weeks prior to BL.
- •Note: Only key inclusion/exclusion criteria mentioned here. Patients will be screened and randomized per the list in the protocol
Outcomes
Primary Outcomes
Psoriasis Area and Severity Index (PASI)
Time Frame: Baseline to Week 16
Percent (%) change in Psoriasis Area and Severity Index (PASI)
Secondary Outcomes
- Psoriasis Area and Severity Index (PASI)(Percent improvement in PASI from BL to Week 8, 12, 24, 32, 42, and 50)
Investigators
Study Sites (30)
Loading locations...
Similar Trials
Completed
Phase 3
Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque PsoriasisPsoriasisNCT04930042Alvotech Swiss AG581
Completed
Phase 2
Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent GlioblastomaRecurrent Glioblastoma (WHO-Grade IV Glioma)NCT03291314Universitair Ziekenhuis Brussel52
Completed
Phase 2
Avelumab Plus Carboplatin-gemcitabine in Urothelial CarcinomaMetastatic Urothelial CancerNCT03390595Associació per a la Recerca Oncologica, Spain85
Active, not recruiting
Phase 2
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Locally Advanced or Metastatic Urothelial CarcinomaNCT05327530EMD Serono Research & Development Institute, Inc.256
Completed
Phase 3
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic TreatmentChronic Plaque PsoriasisNCT00574249Abbott730